Zimmer Biomet announced the departure of David Dvorak, its CEO of ten years. Dan Florin, Senior Vice President and CFO, will serve as interim CEO while the board seeks to fill the position.
Carmell Therapeutics closed a US $4MM Series B financing. Funds will support Phase III clinical development of the company’s Bone Healing Accelerant product.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more